Simcere Zaiming has licensed its first-in-class tri-specific CD79a/CD19/CD3 T-cell engager Sim0660 to Roche for up to $1.53 ...

Carelon Research's Mark Cziraky on why the industry's need for deeper, linked data is driving a shift toward trusted research ...

In March of this year, ACTO co-founder and CEO Parth Khanna wrote a piece for Pharmaceutical Executive discussing an area ...

There is a myth in our industry that when an RBQM implementation fails to deliver the cause must be technical. It was the ...

GSK intends to move its mRNA seasonal influenza vaccine candidate to a Phase III efficacy trial starting in September. The move is based on presented positive Phase II data for it ...

Carelon Research's Mark Cziraky on why the industry's need for deeper, linked data is driving a shift toward trusted research environments.

Nate Hill, co-founder & CEO of Strive Pharmacy, argues that a Category one designation for peptides would give physicians a trusted, regulated channel they currently lack. Nate Hill, Co-Founder & CEO ...

Nate Hill is CEO and Co-Founder of Strive Pharmacy and a national advocate for personalized medicine. With nearly a decade of experience in healthcare, he works to expand access to compounded ...